Optimised versus standard dosing of vancomycin in infants with Gram-positive sepsis (NeoVanc): a multicentre, randomised, open-label, phase 2b, non-inferiority trial

BACKGROUND: Vancomycin is the most widely used antibiotic for neonatal Gram-positive sepsis, but clinical outcome data of dosing strategies are scarce. The NeoVanc programme comprised extensive preclinical studies to inform a randomised controlled trial to assess optimised vancomycin dosing. We comp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet Child Adolesc Health
Main Authors: Hill, Louise F, Clements, Michelle N, Turner, Mark A, Donà, Daniele, Lutsar, Irja, Jacqz-Aigrain, Evelyne, Heath, Paul T, Roilides, Emmanuel, Rawcliffe, Louise, Alonso-Diaz, Clara, Baraldi, Eugenio, Dotta, Andrea, Ilmoja, Mari-Liis, Mahaveer, Ajit, Metsvaht, Tuuli, Mitsiakos, George, Papaevangelou, Vassiliki, Sarafidis, Kosmas, Walker, A Sarah, Sharland, Michael
Formato: Artigo
Idioma:Inglês
Publicado em: 2022
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614674/
https://ncbi.nlm.nih.gov/pubmed/34843669
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S2352-4642(21)00305-9
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados